A derivative of staurosporine (CGP 41:251) shows selectivity for PKC inhibition and in vitro antiproliferative effects as well as in vivo antitumor activity. Int. J. Cancer,43, 851–866 (1989)

A derivative of staurosporine (CGP 41 25

A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti-proliferative as well as In vivo anti-tumor activity

✍ Thomas Meyer; Urs Regenass; Doriano Fabbro; Enrica Alteri; Johannes Röusel; Marc 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 632 KB

Analogues of staurosporine were synthesized and their ability to inhibit protein kinases was examined. Staurosporine is a potent but non-selective inhibitor of in vitro protein kinase C (PKC) activity (K5, 6.0 nn). The derivative CGP 41 25 I had reduced PKC activity with an IC,, of 50 nn but showed